Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affectis Pharmaceuticals has entered into a licensing deal with Merck Serono, a division of Merck KGaA, to develop and commercialize compounds that target P2X7 receptors.
Subscribe to our email newsletter
As per the terms of the agreement, Affectis Pharma will license exclusive rights to Merck for the development and commercialization of the proposed compounds.
Affectis Pharma is entitled to receive a sum of EUR2.4m as an upfront payment and research funding from Merck.
Additionally, Affectis Pharma could receive up to EUR277m in milestones for the first three products to come out of the collaboration, as well as undisclosed royalties from Merck.
Affectis Pharma chief scientist officer Michael Boes said Affectis’ chemistry expertise puts special emphasis on brain penetration, which supports the development of oral P2X7 antagonists for the potential treatment of central nervous system diseases.